Drug Profile
Nanvuranlat - J-Pharma
Alternative Names: JPH-203; JPH-203SBECD; KYT-0353Latest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator J-Pharma
- Class Amines; Antineoplastics; Benzoxazoles; Chlorobenzenes; Phenyl ethers; Small molecules
- Mechanism of Action Amino acid transport system L inhibitors; Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Biliary cancer
- Discontinued Colorectal cancer
Most Recent Events
- 18 Jan 2024 Efficacy data from a phase II trial in Biliary tract cancer presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
- 02 Jun 2023 Efficacy and adverse events data from a phase II trial in Biliary cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 09 Mar 2021 Discontinued - Preclinical for Colorectal cancer in Japan (IV) (J-pharma pipeline, March 2021)